Published in Cancer Weekly, February 13th, 2007
"Progress is continuing toward proof-of-principle with our clinical-stage products," said Stephen A. Hill, president and chief executive officer of ArQule. "Patients have been recruited in a timely fashion, and we expect to begin presenting data from these trials by the middle of this year."
The company has completed dose escalation in its...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.